Cargando…

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer

BACKGROUND: Enhanced activity of histone deacetylases (HDAC) is associated with more aggressive tumour behaviour and tumour progression in various solid tumours. The over-expression of these proteins and their known functions in malignant neoplasms has led to the development of HDAC inhibitors (HDI)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fritzsche, Florian R, Weichert, Wilko, Röske, Annika, Gekeler, Volker, Beckers, Thomas, Stephan, Carsten, Jung, Klaus, Scholman, Katharina, Denkert, Carsten, Dietel, Manfred, Kristiansen, Glen
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631013/ https://www.ncbi.nlm.nih.gov/pubmed/19099586 http://dx.doi.org/10.1186/1471-2407-8-381

Ejemplares similares

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
por: Weichert, W, et al.
Publicado: (2008)

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression
por: Müller, Berit Maria, et al.
Publicado: (2013)

High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo
por: Lehmann, Annika, et al.
Publicado: (2009)

Who Is at Risk for Diagnostic Discrepancies? Comparison of Pre- and Postmortal Diagnoses in 1800 Patients of 3 Medical Decades in East and West Berlin
por: Wittschieber, Daniel, et al.
Publicado: (2012)

Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy
por: Blattmann, Claudia, et al.
Publicado: (2015)

Renal cell neoplasias: reversion-inducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis
por: Rabien, Anja, et al.
Publicado: (2013)

Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA
por: Kristiansen, Ilka, et al.
Publicado: (2017)

Classical pathology and mutational load of breast cancer – integration of two worlds
por: Budczies, Jan, et al.
Publicado: (2015)

Metabolite profiling of human colon carcinoma – deregulation of TCA cycle and amino acid turnover
por: Denkert, Carsten, et al.
Publicado: (2008)

GOLPH2 expression in renal cell cancer
por: Fritzsche, Florian Rudolf, et al.
Publicado: (2008)

Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment
por: Budczies, Jan, et al.
Publicado: (2016)

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort
por: Esgueva, Raquel, et al.
Publicado: (2010)

An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas
por: Noske, Aurelia, et al.
Publicado: (2011)

Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma
por: Weichert, W, et al.
Publicado: (2004)

GOLPH2 expression may serve as diagnostic marker in seminomas
por: Fritzsche, Florian R, et al.
Publicado: (2010)

Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer
por: Kempkensteffen, Carsten, et al.
Publicado: (2009)

ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression
por: Fritzsche, Florian R, et al.
Publicado: (2008)

CD57 Expression in Incidental, Clinically Manifest, and Metastatic Carcinoma of the Prostate
por: Wangerin, Holger, et al.
Publicado: (2014)

In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model
por: Thiemann, Markus, et al.
Publicado: (2012)

The landscape of metastatic progression patterns across major human cancers
por: Budczies, Jan, et al.
Publicado: (2014)

Class I histone deacetylases (HDAC1–3) are histone lysine delactylases
por: Moreno-Yruela, Carlos, et al.
Publicado: (2022)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer
por: Arsenic, Ruza, et al.
Publicado: (2015)

Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer
por: Poyet, Cédric, et al.
Publicado: (2014)

Transcription Regulation by Class III Histone Deacetylases (HDACs)—Sirtuins
por: Dai, Yan, et al.
Publicado: (2008)

Eloquent silence: developmental functions of Class I histone deacetylases
por: Cunliffe, Vincent T
Publicado: (2008)

Class IIa Histone Deacetylases Are Conserved Regulators of Circadian Function
por: Fogg, Paul C. M., et al.
Publicado: (2014)

A Class 1 Histone Deacetylase with Potential as an Antifungal Target
por: Bauer, Ingo, et al.
Publicado: (2016)

The class II histone deacetylases as therapeutic targets for Parkinson’s disease
por: Mazzocchi, Martina, et al.
Publicado: (2020)

Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma
por: Yang, Qiwei, et al.
Publicado: (2022)

The role of class IIa histone deacetylases in regulating endothelial function
por: Shen, Zexu, et al.
Publicado: (2023)

Medicinal chemistry advances in targeting class I histone deacetylases
por: Abdallah, Diaaeldin I., et al.
Publicado: (2023)

Class I histone deacetylase complex: Structure and functional correlates
por: Wang, Xiao, et al.
Publicado: (2023)

Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis
por: Schmidt, Oxana, et al.
Publicado: (2021)

High expression of RelA/p65 is associated with activation of nuclear factor-κB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis
por: Weichert, W, et al.
Publicado: (2007)

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences
por: Kriegsmann, Mark, et al.
Publicado: (2014)

Roles and Targets of Class I and IIa Histone Deacetylases in Cardiac Hypertrophy
por: Kee, Hae Jin, et al.
Publicado: (2011)

Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
por: Sager, Philip T, et al.
Publicado: (2015)

Subcellular Localization of Class I Histone Deacetylases in the Developing Xenopus tectum
por: Guo, Xia, et al.
Publicado: (2016)

Use of class I histone deacetylase inhibitor romidepsin in combination regimens
por: Petrich, Adam, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4anj8vb7aoj5j7aifpdrji47em